One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Zoetis  logo
Zoetis ZTS
$ 79.51 -2.85%
report update icon

Quarterly report 2026-Q3
added 11-05-2026

Zoetis Income Statement 2025-2010 | ZTS

Brief overview of profit and loss at Zoetis

The figures are compared over a five-year interval. According to figures from Zoetis, revenue changed from $6.7 billion to $9.5 billion over five years. Across the full period, sales moved by +41.8%; the average annual rate was 7.2%. The direction is positive, but the growth rate is not particularly high.

Gross profit was 4.6 billion dollars at the start and 6.8 billion dollars at the end of the period (+47.3%). Direct costs grew more slowly than revenue and improved the economics of sales. Gross profit as a share of revenue changed from 69.2% to 71.8%. The business retained more gross profit from each unit of revenue.

The five-year EBITDA result moved by +10.4%: from 441 million dollars to 487 million dollars. Operating performance weakened relative to revenue. EBITDA margin moved from 6.6% to 5.1%. Operating profitability remained broadly stable.

Over the period, net income shifted from 1.6 billion dollars to 2.7 billion dollars (+63.2%). The period finished with its strongest net-income result.

The five-year change in capitalization reached −23%: from 72.8 billion dollars to 56.1 billion dollars. The market has not yet confirmed the improvement in fundamentals.

Financial takeaway

The figures do not all move in the same direction. Key strengths include a stronger final result, sales growth and improving gross profitability. The most visible risks are weaker operating efficiency and lower investor confidence. Further direction will depend on top-line growth, operating profitability, and net income.

Annual Income Statement Zoetis

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010

Market Cap

56.1 B 75.2 B 84.4 B 80.7 B 94.6 B 72.8 B 66 B 41.1 B 38.4 B 26.9 B 21.5 B 21.4 B 15.3 B - - -

Shares

443 M 454 M 461 M 469 M 474 M 476 M 478 M 483 M 490 M 496 M 500 M 501 M 500 M - - -

Historical Prices

126 165 183 172 199 153 133 84.4 74.7 53.1 41.3 40.7 28.6 - - -

Net Income

2.67 B 2.49 B 2.34 B 2.11 B 2.04 B 1.64 B 1.5 B 1.43 B 864 M 821 M 339 M 583 M 504 M 436 M 245 M -

Revenue

9.47 B 9.26 B 8.54 B 8.08 B 7.78 B 6.68 B 6.26 B 5.82 B 5.31 B 4.89 B 4.76 B 4.78 B 4.56 B 4.34 B 4.23 B -

Cost of Revenue

2.67 B 2.72 B 2.56 B 2.45 B 2.3 B 2.06 B 1.99 B 1.91 B 1.78 B 1.67 B 1.74 B 1.72 B 1.67 B 1.56 B 1.65 B -

Gross Profit

6.8 B 6.54 B 5.98 B 5.63 B 5.47 B 4.62 B 4.27 B 3.91 B 3.53 B 3.22 B 3.03 B 3.07 B 2.89 B 2.77 B 2.58 B -

Interest Expense

222 M 225 M 239 M 221 M 224 M 231 M 223 M 206 M 175 M 166 M 124 M 117 M 113 M 31 M 36 M -

EBITDA

487 M 497 M 491 M 465 M 448 M 441 M 2.17 B 2 B 1.82 B 1.48 B 1.13 B 1.03 B 880 M 894 M 701 M -

Operating Expenses

6.8 B 6.54 B 5.98 B 5.63 B 5.47 B 4.62 B 2.25 B 2.03 B 1.81 B 1.82 B 1.96 B 2.1 B 2.07 B 1.94 B 1.95 B -

General and Administrative Expenses

2.38 B 2.32 B 2.15 B 2.01 B 2 B 1.73 B 1.64 B 1.48 B 1.33 B 1.36 B 1.53 B 1.64 B 1.61 B - - -

All numbers in USD currency

Quarterly Income Statement Zoetis

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

412 M 418 M 422 M -1.76 M 443 M 445 M 448 M -1.2 M 453 M 456 M 458 M -728 K 460 M 462 M 464 M -1.11 M 468 M 470 M 472 M -452 K 474 M 475 M 476 M 2 K 476 M 475 M 476 M -572 K 478 M 479 M 480 M -837 K 482 M 484 M 486 M -882 K 489 M 491 M 492 M -585 K 495 M 496 M 497 M -493 K 499 M 500 M 501 M 168 M 501 M 501 M 500 M 2 K 500 M 500 M 500 M - 500 M 500 M 500 M - - - -

Net Income

591 M 691 M 601 M 624 M 721 M 726 M 602 M 581 M 692 M 624 M 599 M 523 M 596 M 670 M 551 M 460 M 528 M 529 M 594 M 413 M 552 M 511 M 558 M 358 M 479 M 376 M 423 M 384 M 433 M 371 M 312 M 345 M 347 M 382 M 350 M 80 M 296 M 247 M 239 M 154 M 237 M 224 M 204 M 20 M 190 M -36 M 165 M 126 M 167 M 139 M 155 M 104 M 131 M 128 M 140 M -10 M 162 M 173 M 111 M - - - -

Revenue

2.39 B 2.47 B 2.26 B 2.37 B 2.42 B 2.47 B 2.2 B 2.32 B 2.39 B 2.36 B 2.19 B 2.21 B 2.15 B 2.18 B 2 B 2.04 B 2 B 2.05 B 1.99 B 1.97 B 1.99 B 1.95 B 1.87 B 1.81 B 1.79 B 1.55 B 1.53 B 1.67 B 1.58 B 1.55 B 1.46 B 1.56 B 1.48 B 1.42 B 1.37 B 1.46 B 1.35 B 1.27 B 1.23 B 1.28 B 1.24 B 1.21 B 1.16 B 1.27 B 1.21 B 1.18 B 1.1 B 1.32 B 1.21 B 1.16 B 1.1 B 1.25 B 1.1 B 1.11 B 1.09 B 1.18 B 1.02 B 1.09 B 1.05 B - - - -

Cost of Revenue

698 M 673 M 641 M 687 M 697 M 664 M 618 M 707 M 701 M 668 M 643 M 728 M 638 M 607 M 588 M 653 M 607 M 625 M 569 M 600 M 586 M 568 M 549 M 601 M 546 M 451 M 459 M 530 M 479 M 465 M 518 M 544 M 473 M 447 M 447 M 457 M 435 M 440 M 443 M 468 M 410 M 399 M 389 M 496 M 421 M 427 M 394 M 491 M 434 M 413 M 379 M 466 M 385 M 416 M 402 M - 359 M 378 M 393 M - - - -

Gross Profit

1.69 B 1.8 B 1.62 B 1.69 B 1.72 B 1.81 B 1.58 B 1.61 B 1.69 B 1.69 B 1.55 B 1.48 B 1.51 B 1.57 B 1.41 B 1.39 B 1.4 B 1.43 B 1.42 B 1.37 B 1.4 B 1.38 B 1.32 B 1.21 B 1.24 B 1.1 B 1.08 B 1.14 B 1.1 B 1.08 B 937 M 1.02 B 1.01 B 968 M 919 M 1 B 912 M 829 M 788 M 809 M 831 M 809 M 773 M 778 M 793 M 748 M 708 M 829 M 776 M 745 M 718 M 788 M 718 M 698 M 688 M - - - - - - - -

Interest Expense

-3 M -2 M -1 M -7 M -1 M -1 M 3 M 1 M -2 M 2 M -5 M 4 M -4 M 2 M -5 M 6 M 1 M 6 M 1 M -3 M 3 M -2 M -2 M -4 M -2 M 58 M 1 M 1 M -1 M 1 M -1 M -3 M 19 M -1 M 47 M -2 M 43 M 3 M 5 M -3 M 1 M 5 M -1 M 4 M 3 M -3 M 1 M -2 M 1 M 29 M -2 M 4 M -1 M 1 M -2 M - 7 M 8 M 8 M - - - -

EBITDA

39 M 38 M 39 M 38 M 39 M 40 M 40 M 42 M 42 M 42 M 44 M 44 M 46 M 48 M 47 M 46 M 48 M 47 M 52 M 50 M 51 M 52 M 51 M 52 M 56 M 61 M 62 M 61 M 60 M 58 M 58 M 61 M 45 M 26 M 25 M 25 M 26 M 24 M 25 M 23 M 24 M 24 M 24 M 17 M 16 M 16 M 15 M 16 M 15 M 16 M 15 M 16 M 16 M 16 M 16 M - 54 M 54 M 48 M - - - -

Operating Expenses

- 1.8 B 1.62 B - 1.72 B 1.81 B 1.58 B 1.61 B 1.69 B 1.69 B 1.55 B 1.48 B 1.51 B 1.57 B 1.41 B 1.39 B 1.4 B 1.43 B 1.42 B 1.37 B 1.4 B 1.38 B 1.32 B 1.21 B 1.24 B 1.1 B 1.08 B 1.14 B 1.1 B 1.08 B 937 M 1.02 B 1.01 B 968 M 919 M 1 B 912 M 829 M 788 M 809 M 831 M 809 M 773 M 778 M 793 M 748 M 708 M 829 M 776 M 745 M 718 M 788 M 718 M 698 M 688 M - - - - - - - -

General and Administrative Expenses

582 M 592 M 588 M 608 M 582 M 614 M 574 M 625 M 565 M 581 M 547 M 565 M 525 M 556 M 505 M 514 M 501 M 529 M 465 M 593 M 504 M 495 M 409 M 520 M 424 M 393 M 389 M 472 M 391 M 406 M 369 M 420 M 367 M 359 M 338 M 361 M 328 M 336 M 309 M 361 M 345 M 343 M 315 M 425 M 374 M 379 M 354 M 497 M 394 M 396 M 356 M 458 M 399 M 399 M 357 M - 335 M 344 M 338 M - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Zoetis (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Curis Curis
CRIS
$ 0.88 3.67 % $ 11.6 M usaUSA
Cyclerion Therapeutics Cyclerion Therapeutics
CYCN
$ 34.99 3.77 % $ 147 M usaUSA
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
CorMedix CorMedix
CRMD
$ 5.31 1.43 % $ 383 K usaUSA
Novartis AG Novartis AG
NVS
$ 162.64 0.44 % $ 315 B schweizSchweiz
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 50.09 3.15 % $ 4.5 B schweizSchweiz
PDS Biotechnology Corporation PDS Biotechnology Corporation
PDSB
$ 1.22 4.27 % $ 56.6 M usaUSA
Pfizer Pfizer
PFE
$ 29.39 -0.22 % $ 167 B usaUSA
Pharming Group N.V. Pharming Group N.V.
PHAR
$ 12.32 0.16 % $ 8.49 B niderlandNiderland
Orgenesis Orgenesis
ORGS
- -33.86 % $ 61.2 M usaUSA
Cytokinetics, Incorporated Cytokinetics, Incorporated
CYTK
$ 53.74 -3.26 % $ 6.45 M usaUSA
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia
Prothena Corporation plc Prothena Corporation plc
PRTA
$ 7.93 0.51 % $ 427 M usaUSA
Codiak BioSciences Codiak BioSciences
CDAK
- -55.98 % $ 2.15 M usaUSA
DBV Technologies S.A. DBV Technologies S.A.
DBVT
$ 10.54 7.55 % $ 1.47 B franceFrance
Rocket Pharmaceuticals Rocket Pharmaceuticals
RCKT
$ 2.38 -2.05 % $ 264 M usaUSA
Regeneron Pharmaceuticals Regeneron Pharmaceuticals
REGN
$ 904.69 0.2 % $ 94.6 B usaUSA
Replimune Group Replimune Group
REPL
$ 21.67 8.24 % $ 2.01 B usaUSA
DiaMedica Therapeutics DiaMedica Therapeutics
DMAC
$ 9.47 4.76 % $ 445 M usaUSA
Royalty Pharma plc Royalty Pharma plc
RPRX
$ 67.31 -0.39 % $ 28.9 B usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA
Rhythm Pharmaceuticals Rhythm Pharmaceuticals
RYTM
$ 111.51 6.18 % $ 7.25 B usaUSA
Puma Biotechnology Puma Biotechnology
PBYI
$ 8.28 -15.25 % $ 414 M usaUSA
SIGA Technologies SIGA Technologies
SIGA
$ 3.12 4.55 % $ 223 M usaUSA
Sage Therapeutics Sage Therapeutics
SAGE
- - $ 527 M usaUSA
Taro Pharmaceutical Industries Ltd. Taro Pharmaceutical Industries Ltd.
TARO
- - $ 1.62 B israelIsrael
Sol-Gel Technologies Ltd. Sol-Gel Technologies Ltd.
SLGL
$ 61.62 -2.21 % $ 172 M israelIsrael
SELLAS Life Sciences Group SELLAS Life Sciences Group
SLS
$ 8.41 6.73 % $ 917 M usaUSA
Summit Therapeutics Summit Therapeutics
SMMT
$ 16.34 15.15 % $ 12.2 B britainBritain
Cabaletta Bio Cabaletta Bio
CABA
$ 1.3 1.17 % $ 131 M usaUSA
Syndax Pharmaceuticals Syndax Pharmaceuticals
SNDX
$ 9.53 1.39 % $ 826 M usaUSA
Sanofi Sanofi
SNY
$ 47.06 0.32 % $ 57.4 B franceFrance
Forma Therapeutics Holdings Forma Therapeutics Holdings
FMTX
- - $ 958 M usaUSA
Blueprint Medicines Corporation Blueprint Medicines Corporation
BPMC
- - $ 8.14 B usaUSA
Horizon Therapeutics Public Limited Company Horizon Therapeutics Public Limited Company
HZNP
- - $ 26.6 B irlandaIrlanda
Sarepta Therapeutics Sarepta Therapeutics
SRPT
$ 17.8 0.68 % $ 1.78 B usaUSA
Paratek Pharmaceuticals Paratek Pharmaceuticals
PRTK
- - $ 121 M usaUSA
China SXT Pharmaceuticals China SXT Pharmaceuticals
SXTC
$ 2.84 -3.07 % $ 1.93 M chinaChina
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
TAK
$ 21.02 -0.92 % $ 33.2 B japanJapan
Tarsus Pharmaceuticals Tarsus Pharmaceuticals
TARS
$ 68.11 0.87 % $ 2.85 B usaUSA
ASLAN Pharmaceuticals Limited ASLAN Pharmaceuticals Limited
ASLN
- -14.27 % $ 1.7 M singaporeSingapore
Bio-Techne Corporation Bio-Techne Corporation
TECH
$ 72.78 0.17 % $ 11.4 B usaUSA
Teva Pharmaceutical Industries Limited Teva Pharmaceutical Industries Limited
TEVA
$ 42.32 1.33 % $ 48.5 B israelIsrael
RedHill Biopharma Ltd. RedHill Biopharma Ltd.
RDHL
$ 0.43 0.45 % $ 5.3 B israelIsrael
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Unity Biotechnology Unity Biotechnology
UBX
- -33.41 % $ 3.37 M usaUSA
iTeos Therapeutics iTeos Therapeutics
ITOS
- - $ 411 M usaUSA
Shattuck Labs Shattuck Labs
STTK
$ 4.59 2.78 % $ 319 M usaUSA
Seelos Therapeutics Seelos Therapeutics
SEEL
- -47.76 % $ 6.27 M usaUSA
Evogene Ltd. Evogene Ltd.
EVGN
$ 0.28 -16.14 % $ 2.2 M israelIsrael